🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 2 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/09/1991 | 5,06 | 5,06 | 4,88 | 5,06 | +3,85% | 3,70% | 30.200 |
| 09/09/1991 | 5,00 | 5,13 | 4,88 | 4,88 | -2,50% | 5,00% | 33.800 |
| 06/09/1991 | 5,13 | 5,13 | 5,00 | 5,00 | +0,00% | 2,44% | 35.800 |
| 05/09/1991 | 5,00 | 5,19 | 5,00 | 5,00 | +0,00% | 3,75% | 145.000 |
| 04/09/1991 | 5,13 | 5,25 | 5,00 | 5,00 | -2,44% | 4,88% | 139.000 |
| 03/09/1991 | 5,19 | 5,50 | 5,13 | 5,13 | -1,20% | 7,23% | 326.200 |
| 30/08/1991 | 4,94 | 5,19 | 4,81 | 5,19 | +5,06% | 7,59% | 145.800 |
| 29/08/1991 | 4,69 | 4,94 | 4,56 | 4,94 | +5,33% | 8,00% | 178.000 |
| 28/08/1991 | 4,63 | 4,69 | 4,50 | 4,69 | +1,35% | 4,05% | 73.400 |
| 27/08/1991 | 4,56 | 4,69 | 4,50 | 4,63 | +1,37% | 4,11% | 72.600 |
| 26/08/1991 | 4,50 | 4,56 | 4,31 | 4,56 | +5,80% | 5,56% | 77.600 |
| 23/08/1991 | 4,50 | 4,50 | 4,31 | 4,31 | -1,43% | 4,17% | 17.000 |
| 22/08/1991 | 4,44 | 4,50 | 4,31 | 4,38 | -1,41% | 4,23% | 41.400 |
| 21/08/1991 | 4,44 | 4,44 | 4,31 | 4,44 | +1,43% | 2,82% | 14.000 |
| 20/08/1991 | 4,38 | 4,44 | 4,25 | 4,38 | +0,00% | 4,29% | 57.800 |
| 19/08/1991 | 4,44 | 4,50 | 4,19 | 4,38 | -2,78% | 7,04% | 75.400 |
| 16/08/1991 | 4,63 | 4,63 | 4,50 | 4,50 | +0,00% | 2,70% | 69.800 |
| 15/08/1991 | 4,50 | 4,63 | 4,50 | 4,50 | -2,70% | 2,78% | 31.800 |
| 14/08/1991 | 4,63 | 4,63 | 4,56 | 4,63 | +2,78% | 1,35% | 102.200 |
| 13/08/1991 | 4,63 | 4,63 | 4,50 | 4,50 | +0,00% | 2,70% | 63.000 |
| 12/08/1991 | 4,50 | 4,63 | 4,50 | 4,50 | +0,00% | 2,78% | 41.600 |
| 09/08/1991 | 4,50 | 4,63 | 4,50 | 4,50 | -1,37% | 2,78% | 172.000 |
| 08/08/1991 | 4,63 | 4,63 | 4,50 | 4,56 | +1,39% | 2,70% | 97.000 |
| 07/08/1991 | 4,63 | 4,63 | 4,50 | 4,50 | -2,70% | 2,70% | 222.400 |
| 06/08/1991 | 4,56 | 4,63 | 4,56 | 4,63 | +0,00% | 1,37% | 124.600 |
| 05/08/1991 | 4,63 | 4,63 | 4,50 | 4,63 | +1,37% | 2,70% | 103.800 |
| 02/08/1991 | 4,63 | 4,63 | 4,56 | 4,56 | +1,39% | 1,35% | 220.800 |
| 01/08/1991 | 4,50 | 4,56 | 4,50 | 4,50 | +0,00% | 1,39% | 157.000 |
| 31/07/1991 | 4,63 | 4,63 | 4,50 | 4,50 | +0,00% | 2,70% | 372.000 |
| 30/07/1991 | 4,63 | 4,63 | 4,50 | 4,50 | -2,70% | 2,70% | 354.400 |